<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drugs used in the treatment of &lt;EM&gt;Pneumocystis &lt;/EM&gt;pneumonia (PCP) in adults and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drugs used in the treatment of <em>Pneumocystis </em>pneumonia (PCP) in adults and adolescents</h1>
<div class="graphic"><div class="figure"><div class="ttl">Drugs used in the treatment of <em>Pneumocystis </em>pneumonia (PCP) in adults and adolescents</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Dose</td> <td class="subtitle1">Major adverse reactions</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Preferred regimen</td> </tr> <tr class="divider_bottom"> <td class="indent1">TMP-SMX</td> <td>TMP-SMX (15 to 20 mg/kg/day of the trimethoprim component) orally or IV given in three or four divided doses*<sup>¶</sup></td> <td>Rash (rarely SJS/TEN), fever, neutropenia, hyperkalemia, transaminase elevations, photosensitivity, increased serum creatinine</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Alternative regimens</td> </tr> <tr> <td class="indent1" rowspan="2">TMP <strong>plus</strong> dapsone<sup>Δ</sup></td> <td>TMP: 5 mg/kg orally three times daily<sup>¶</sup></td> <td>Trimethoprim: Rash, gastrointestinal distress, transaminase elevation, neutropenia, hyperkalemia</td> </tr> <tr> <td>Dapsone: 100 mg orally once per day</td> <td>Dapsone: Rash, fever, lymphadenopathy, transaminase elevations (sulfone hypersensitivity syndrome), gastrointestinal upset, methemoglobinemia, hemolytic anemia</td> </tr> <tr> <td class="indent1" rowspan="2">Primaquine<sup>Δ</sup> <strong>plus</strong> clindamycin*</td> <td>Primaquine: 30 mg (base) orally once per day</td> <td>Primaquine: Rash, fever, gastrointestinal distress, methemoglobinemia, hemolytic anemia, leukopenia, neutropenia</td> </tr> <tr> <td>Clindamycin: 900 mg IV every eight hours <strong>OR</strong> 600 mg IV every six hours <strong>OR</strong> 600 mg orally three times daily <strong>OR</strong> 450 mg orally four times daily</td> <td>Clindamycin: Rash, diarrhea, <em>Clostridioides </em><em>difficile </em>colitis, abdominal pain</td> </tr> <tr> <td class="indent1">Atovaquone suspension</td> <td>750 mg orally twice daily (must be taken with food)</td> <td>Gastrointestinal distress, fever, transaminase elevation, rash (less frequently than with other regimens)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Pentamidine<sup>◊</sup></td> <td>4 mg/kg IV once daily<sup>¶</sup></td> <td> <p>Nephrotoxicity, infusion reactions, hyperkalemia, hyperglycemia, pancreatitis, cardiac arrhythmias (including TdP), transaminase elevations, hypotension, hypoglycemia, hypokalemia, hypocalcemia</p> <p>Certain adverse effects can be life threatening (eg, hypoglycemia and hypotension)<sup>§</sup></p> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Adjunctive glucocorticoids<sup>§</sup></td> </tr> <tr> <td class="indent1">Prednisone</td> <td> <p>40 mg orally twice daily for five days, followed by</p> <p>40 mg orally once daily for five days, followed by</p> 20 mg orally once daily for 11 days</td> <td> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Patients should receive 21 days of therapy.</div><div class="graphic_footnotes">TMP-SMX: trimethoprim-sulfamethoxazole (cotrimoxazole); IV: intravenously; SJS/TEN: Stevens-Johnson syndrome and toxic epidermal necrolysis; TdP: torsades de pointes; G6PD: glucose-6-phosphate dehydrogenase.<br/>* IV preferred in patients with PaO<sub>2</sub> &lt;60 mmHg, respiratory rate &gt;25 or respiratory fatigue, unable to take oral medications.<br/>¶ Dose shown in table is for patients with normal renal function. Dose modification for renal impairment may be needed.<br/>Δ Check for G6PD deficiency.<br/>◊ Pentamidine should only be used for patients with severe disease. Individuals requiring pentamidine should be admitted to the hospital and closely monitored with bedside telemetry and frequent measurement of blood pressure. Pentamidine dose may be reduced to 3 mg/kg IV daily due to toxicity. Refer to accompanying text.<br/>§ Adjunctive glucocorticoids should be given to patients with a room air PaO<sub>2</sub> &lt;70 mmHg, an alveolar-arterial (A-a) oxygen gradient ≥35 mmHg, and/or evidence of hypoxemia (eg, room air O<sub>2</sub> saturation &lt;92 percent). IV methylprednisolone can be administered as 75 percent of prednisone dose.</div><div class="graphic_reference">Prepared with data from: DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. (Updated April 22, 2015.)</div><div id="graphicVersion">Graphic 61052 Version 15.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
